Astellas Pharma Inc.
↗Tokyo, Japan
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company founded on April 1, 2005, through the merger of Yamanouchi Pharmaceutical Co., Ltd. (founded 1923) and Fujisawa Pharmaceutical Co., Ltd. (founded 1894). The company discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals with a diverse portfolio spanning oncology, urology, ophthalmology, immunology, and women's health. With 13,643 employees and operations in approximately 70 countries, Astellas is known for blockbuster drugs including XTANDI (prostate cancer), PADCEV (urothelial cancer), VEOZAH (vasomotor symptoms), Myrbetriq/Betanis (overactive bladder), and Prograf (immunosuppression for transplantation). The company operates multiple R&D and manufacturing facilities across Japan, the United States, Europe, and Asia, positioning itself as a specialty pharmaceutical company focused on immuno-oncology, gene therapy, mitochondrial disorders, rare blindness, regenerative medicine, and targeted protein degradation.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals, Oncology, Immunology
SIZE & FINANCIALS
Employees:10000+
Revenue:$12.5B-$13.2B
Founded:2005
Ownership:public
Status:operating
FUNDING
Stage:Public Company
STOCK
Exchange:Tokyo Stock Exchange (TSE) and NASDAQ
Ticker:4503.T (TSE), ALPMY (NASDAQ ADR)
Market Cap:$23.17B
PIPELINE
Stage:Discovery to Phase 3
Lead Drug Stage:Phase 3 and Commercial
Modalities:Small molecule, Monoclonal antibodies, Antibody-drug conjugates (ADC), Bispecific antibodies, Gene therapy, Cell therapy, Targeted protein degraders
Active Trials:181
Trial Phases:Phase 1: 254 | Phase 2: 39 | Phase 3: 29 | Phase 4: 10
FDA Approvals:15
EMA Approvals:12
CORPORATE STRUCTURE
Subsidiaries:Astellas Pharma US, Inc., Astellas Gene Therapies, Astellas Pharma Europe Ltd, Astellas Pharma China, Astellas Oncology subsidiaries
Key Partnerships:Pfizer: Co-development and marketing partner for XTANDI (enzalutamide), MSD (Merck Sharp & Dohme): Combination studies with Keytruda (pembrolizumab) for PADCEV, YASKAWA: Joint venture for cell therapy manufacturing facility (March 2025), Evopoint Biosciences: Exclusive worldwide license agreement for XNW27011 (CLDN18.2-targeting ADC) excluding China (May 2025), Taysha Gene Therapies: Strategic investment to support AAV-based gene therapy programs, Nikon: Partnership providing access to advanced imaging capabilities (June 2025), Mitsubishi Research Institute: Supporting pharma startups in Japan (June 2025), Korea Institute for Startup and Entrepreneurship Development: Support for Korean startups' drug discovery and global expansion (July 2025)
COMPETITION
Position:Challenger
Competitors:Roche, Novartis, Merck & Co., Johnson & Johnson, Pfizer, GSK, AbbVie, Bristol Myers Squibb +4 more
LEADERSHIP
Key Executives:
Naoki Okamura - President and CEO
Kenji Yasukawa - Chairman of the Board
Adam Pearson - Chief Strategy Officer
Atsushi Kitamura - Chief Financial Officer
Katsuyoshi Sugita - Chief People Officer & Chief Ethics & Compliance Officer
Nick Eshkenazi - Chief Digital & Transformation Officer
Rao V. Mantri, Ph.D. - Chief Manufacturing Officer
Tatjana Dragovic - General Counsel and Chief Ethics & Compliance Officer
Scientific Founders:Yamanouchi Pharmaceutical (founded 1923, merged to form Astellas), Fujisawa Pharmaceutical (founded 1894, merged to form Astellas)
Board Members:Kenji Yasukawa (Representative Director, Chairman of the Board), Naoki Okamura (Representative Director, President and CEO), Katsuyoshi Sugita (Representative Director, Executive Vice President), Takashi Tanaka (Outside Director), Eriko Sakurai (Outside Director), Masahiro Miyazaki (Outside Director), Yoichi Ohno (Outside Director), Andreas Busch (Outside Director), Mark Enyedy (Outside Director), Rika Hirota (Director, Audit & Supervisory Committee Member), Mika Nakayama (Outside Director, Audit & Supervisory Committee Member), Rie Akiyama (Outside Director, Audit & Supervisory Committee Member), Tomoko Aramaki (Outside Director, Audit & Supervisory Committee Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Astellas Pharma Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.